Frank R. Lichtenberg
YOU?
Author Swipe
View article: The Long-Run Impact of Changes in Prescription Drug Sales on Mortality and Hospital Utilization in Belgium, 1998–2019
The Long-Run Impact of Changes in Prescription Drug Sales on Mortality and Hospital Utilization in Belgium, 1998–2019 Open
Objectives: We investigate the long-run impact of changes in prescription drug sales on mortality and hospital utilization in Belgium during the first two decades of the 21st century. Methods: We analyze the correlation across diseases bet…
View article: The impact of biomedical innovation on US mortality, 1999–2019: evidence partly based on 286 million descriptors of 27 million PubMed articles
The impact of biomedical innovation on US mortality, 1999–2019: evidence partly based on 286 million descriptors of 27 million PubMed articles Open
We investigate whether the diseases for which there was more biomedical innovation had larger 1999–2019 reductions in premature mortality. Biomedical innovation related to a disease is measured by the change in the mean vintage of descript…
View article: Prevalence and relationship with health of off-label and contraindicated drug use in the United States: a cross-sectional study
Prevalence and relationship with health of off-label and contraindicated drug use in the United States: a cross-sectional study Open
Off-label and contraindicated drug use is prevalent in outpatient prescriptions and is associated with worse health outcomes and increased healthcare utilisation. These findings suggest a need for enhanced monitoring and regulatory measure…
View article: Do newer drugs treat fewer diseases, controlling for time since launch? Evidence from France and the U.S.
Do newer drugs treat fewer diseases, controlling for time since launch? Evidence from France and the U.S. Open
More recently approved drugs are less likely to be 'general-purpose technologies' (or even multi-purpose technologies) than older drugs. The relative importance of 'precision medicine' has increased in recent decades. Drugs that have fewer…
View article: Racial and gender disparities in the effect of new drug approvals on U.S. cancer mortality
Racial and gender disparities in the effect of new drug approvals on U.S. cancer mortality Open
Objective: To investigate whether there were racial and gender disparities in the effect of new drug approvals on U.S. cancer mortality since 1990. Study design: We estimate two-way (by cancer site and year (1990–2019)) fixed-effects model…
View article: The Relationship Between Pharmaceutical Innovation and Cancer Mortality in Spain, From 1999 to 2016
The Relationship Between Pharmaceutical Innovation and Cancer Mortality in Spain, From 1999 to 2016 Open
The cancer sites for which there were more pharmaceutical innovation-more new drugs authorized-had larger 1999 to 2016 reductions in mortality in Spain, controlling for the lagged change in cancer incidence.
View article: The impact of biomedical innovation on the disability of elderly Medicare recipients, 2013–2019
The impact of biomedical innovation on the disability of elderly Medicare recipients, 2013–2019 Open
Formulae display:?Mathematical formulae have been encoded as MathML and are displayed in this HTML version using MathJax in order to improve their display. Uncheck the box to turn MathJax off. This feature requires Javascript. Click on a f…
View article: The Effects of Off-label Drug Use on Disability and Medical Expenditure
The Effects of Off-label Drug Use on Disability and Medical Expenditure Open
Does using prescription drugs off-label increase disability and medical expenditure? This paper uses a unique dataset to evaluate off-label vs. on-label drug use in the US non-institutionalized population. Patients using drugs off-label ha…
View article: The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998–2017
The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998–2017 Open
Pharmaceutical innovation-the introduction and use of new drugs-substantially increased cancer survival rates in New Zealand, and substantially reduced premature (before ages 85, 75, and 65) cancer mortality there during the period 1998-20…
View article: The Health Impact of, and access to, New Drugs in Korea
The Health Impact of, and access to, New Drugs in Korea Open
We perform an econometric assessment of the role that pharmaceutical innovation—
\nthe introduction and use of new drugs—has played in improving the health of Koreans,
\nby investigating whether diseases for which more new drugs were launc…
View article: How cost-effective are new cancer drugs in the U.S.?
How cost-effective are new cancer drugs in the U.S.? Open
Introduction: More than 8 times as many new cancer drugs were approved during 2005-2015 as were approved during 1975-1985 (66 vs. 8). The average annual 2010-2014 growth rate of U.S. cancer drug expenditure was 7.6%. This has contributed t…
View article: The impact of pharmaceutical innovation on the burden of disease in Ireland, 2000–2015
The impact of pharmaceutical innovation on the burden of disease in Ireland, 2000–2015 Open
Background We perform an econometric assessment of the impact that pharmaceutical innovation had on the burden of disease in Ireland. Methods We use a difference-in-differences (or two-way fixed effects) research design: we investigate whe…
View article: How many life-years have new drugs saved? A three-way fixed-effects analysis of 66 diseases in 27 countries, 2000–2013
How many life-years have new drugs saved? A three-way fixed-effects analysis of 66 diseases in 27 countries, 2000–2013 Open
Background We analyzed the role that the launch of new drugs has played in reducing the number of years of life lost (YLL) before three different ages (85, 70 and 55 y) due to 66 diseases in 27 countries. Methods We estimated two-way fixed…
View article: The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger
The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger Open
Dual antiplatelet therapy, combining a P2Y12 inhibitor and aspirin, is central to the management of patients with acute coronary syndromes. Clopidogrel is a commonly prescribed thienopyridine P2Y12 inhibitor used to prevent secondary event…
View article: How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013
How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013 Open
We analyze the role that the launch of new drugs has played in reducing the number of years of life lost (YLL) before 3 different ages (85, 70, and 55) due to 66 diseases in 27 countries. We estimate 2-way fixed-effects models of the rate …
View article: How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013
How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013 Open
We analyze the role that the launch of new drugs has played in reducing the number of years of life lost (YLL) before 3 different ages (85, 70, and 55) due to 66 diseases in 27 countries.We estimate 2-way fixed-effects models of the rate o…
View article: The Long-run Impact of New Medical Ideas on Cancer Survival and Mortality
The Long-run Impact of New Medical Ideas on Cancer Survival and Mortality Open
I investigate whether the types of cancer (breast, colon, lung, etc.) subject to greater penetration of new ideas had larger subsequent survival gains and mortality reductions, controlling for changing incidence.I use the MEDLINE/PubMED da…
View article: The Impact of New Drug Launches on Longevity Growth in Nine Middle Eastern and African Countries, 2007–2015
The Impact of New Drug Launches on Longevity Growth in Nine Middle Eastern and African Countries, 2007–2015 Open
This study provides econometric evidence about the impact that new chemical entity (NCE) launches had on premature mortality from 17 diseases in 9 Middle Eastern and African countries during the period 2007–2015. The greater the relative n…